DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Hermansky-Pudlak syndrome 2 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHermansky-Pudlak syndrome 2 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hermansky-pudlak syndrome 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
adaptor related protein complex 3 subunit beta 1 (AP3B1) — AP3B1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gtpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9C5A · 4.2 Å · ligand GUANOSINE-5'-TRIPHOSPHATE (GTP). Experimental structure, not a prediction.
What the evidence adds up to
Hermansky-Pudlak syndrome is a rare autosomal recessive disorder characterised by oculocutaneous albinism, platelet storage pool deficiency causing a bleeding diathesis, and accumulation of ceroid lipofuscin. The syndrome was first described in 1959. Affected individuals may also develop pulmonary fibrosis, granulomatous colitis, and less commonly cardiomyopathy, renal dysfunction, and neutropenia. The condition has been reported globally but is most frequent in a cluster population in northwest Puerto Rico, where the carrier incidence is 1 in 21. The majority of HPS genes have been described as novel, though a conserved protein family including HPS4 has been identified, suggesting the cellular machinery involved is ancient.
Major organ involvement typically includes pulmonary fibrosis and granulomatous colitis. A case report of an HPS patient with pulmonary fibrosis describes this as a major complication. The systemic extent of the disease creates multiple anaesthetic concerns, requiring detailed preoperative evaluation and close perioperative monitoring. In pregnancy, affected individuals may suffer from blindness, pulmonary fibrosis, colitis, and bleeding diathesis. A case of the oldest historical patient with HPS type 6 and associated gastrointestinal management has been reported.
One case series addresses the safety of cardiac catheterisation in HPS subtype 5 patients with bleeding diathesis. The abstract notes that defective platelet aggregation presents a potential challenge to clinicians. No specific drug treatment for the underlying syndrome is mentioned in any of these abstracts. The management described is supportive and procedural: gastrointestinal management, anaesthetic precautions, and monitoring during invasive procedures.
What is still missing are any controlled trials of pharmacological interventions, data on whether any drug can modify the course of pulmonary fibrosis or colitis in HPS, and patient stratification by HPS subtype. The rarity of the condition makes recruitment for such trials difficult, and no funding for a repurposing study is described in these reports.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Clinical Gastroenterology · 2010 · 37 citations
The Management of Gastrointestinal Disease in Hermansky-Pudlak Syndrome
AbstractHermansky-Pudlak syndrome (HPS) was first described in 1959 by Hermansky and Pudlak. Clinically, HPS is characterized by oculocutaneous albinism, platelet storage pool deficiency, and ceroid tissue accumulation. It is a rare disorder that has been described globally but has the highest frequency in a cluster population in Puerto Rico. HPS patients also have major organ involvement that typically includes pulmonary fibrosis and granulomatous colitis. Rarely have cardiomyopathy and renal dysfunction been described. We report a case of the oldest historical patient with HPS type 6 and the associated gastrointestinal management.
The CHiPS Domain – Ancient Traces for the Hermansky–Pudlak Syndrome
AbstractHermansky-Pudlak syndrome (HPS) is a rare disorder caused by malfunctions of lysosomes and specialized lysosome-related organelles, resulting primarily in oculocutaneous albinism and bleeding diathesis. The majority of the HPS genes have been described as novel, but herein we report the identification of a conserved protein family which includes human HPS4, as well as distant homologs for other HPS genes. Our results suggest that the cellular machinery involved in the HPS syndrome is ancient.
American Journal of Perinatology · 2009 · 5 citations
Hermansky-Pudlak Syndrome in Pregnancy
AbstractHermansky-Pudlak syndrome (HPS) is a multisystem, autosomal-recessive disorder characterized by oculocutaneous albinism, platelet storage pool deficiency resulting in prolonged bleeding, and ceroid lipofuscin deposition. Affected individuals may suffer from blindness, pulmonary fibrosis, colitis, and bleeding diathesis. Although it has been reported in various ethnic groups, HPS is most common in individuals from the northwest corner of Puerto Rico, with a carrier incidence of 1 in 21.
The Journal of Association of Chest Physicians · 2014 · 4 citations · open access
Hermansky-Pudlak syndrome: A case report
AbstractHermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disorder, which results in oculocutaneous albinism, bleeding disorders, and storage of abnormal fat protein compound (liposomal accumulation of ceroid lipofuscin). The major complications of this disorder are pulmonary fibrosis (PF) and colitis. This is a case report of an HPS patient with PF.
Open Journal of Anesthesiology · 2015 · 1 citations · open access
Anesthetic Management of a Patient with Hermansky-Pudlak Syndrome
AbstractHermansky-Pudlak Syndrome (HPS) is a rare genetic condition characterized by platelet function abnormalities and oculocutaneous albinism. Other systemic manifestations of the disease include pulmonary fibrosis, granulomatous colitis, impaired renal function, and cardiomyopathy. Due to the systemic extent of the disease, HPS has multiple anesthetic concerns and requires a detailed preoperative evaluation and close perioperative monitoring.
Journal of Case Reports and Images in Medicine · 2021 · 0 citations · open access
Hermansky-Pudlak syndrome subtype 5 (HPS-5): Safety of cardiac catheterization in patients with a bleeding diathesis
AbstractIntroduction: Hermansky-Pudlak syndrome is a rare autosomal recessive form of albinism that leads to defective platelet aggregation and bleeding diathesis. This presents a potential challenge to clinicians involved in the care of these patients. Common manifestations include nystagmus, lighter skin, and hair color than family members, prolonged bleeding after minor procedures, pulmonary fibrosis, colitis, and neutropenia.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
